232 related articles for article (PubMed ID: 19009980)
1. Activation of complement by Mycobacterium leprae requires disruption of the bacilli.
Lahiri R; Sandoval FG; Krahenbuhl JL; Shannon EJ
Lepr Rev; 2008 Sep; 79(3):311-4. PubMed ID: 19009980
[TBL] [Abstract][Full Text] [Related]
2. In vitro thalidomide does not interfere with the activation of complement by M. leprae.
Shannon EJ; Sandoval FG; Morales MJ
J Drugs Dermatol; 2011 Mar; 10(3):274-8. PubMed ID: 21369644
[TBL] [Abstract][Full Text] [Related]
3. Selective decrease of M. leprae-specific IgG1 and IgG3 antibodies in leprosy patients associated with ENL.
Kifayet A; Hussain R
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):105-14. PubMed ID: 8690967
[TBL] [Abstract][Full Text] [Related]
4. Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.
Amorim FM; Nobre ML; Nascimento LS; Miranda AM; Monteiro GRG; Freire-Neto FP; Queiroz MDCP; Queiroz JW; Duthie MS; Costa MR; Reed SG; Johnson WD; Dupnik KM; Jeronimo SMB
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007089. PubMed ID: 30689631
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy.
Rao TD; Rao PR
Int J Lepr Other Mycobact Dis; 1987 Mar; 55(1):36-41. PubMed ID: 3549939
[TBL] [Abstract][Full Text] [Related]
6. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients.
Andreoli A; Brett SJ; Draper P; Payne SN; Rook GA
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):211-7. PubMed ID: 3894538
[TBL] [Abstract][Full Text] [Related]
7. Towards understanding the pathology of erythema nodosum leprosum.
Kahawita IP; Lockwood DN
Trans R Soc Trop Med Hyg; 2008 Apr; 102(4):329-37. PubMed ID: 18313706
[TBL] [Abstract][Full Text] [Related]
8. Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10.
Pacheco FS; Prata RBDS; Brandão SS; Ferreira H; Rodrigues TF; Brandão Dos Santos J; da Silva CO; Tavares IF; Mendes MA; Rodrigues ACDP; Machado AM; Nery JADC; Amadeu TP; Moraes MO; Sarno EN; Schmitz V
Immunohorizons; 2020 Feb; 4(2):47-56. PubMed ID: 32034084
[TBL] [Abstract][Full Text] [Related]
9. Immunological methods employed in an attempt to induce erythema nodosum leprosum (ENL) in mice.
Anthony J; Vaidya MC; Dasgupta A
Lepr India; 1978 Jul; 50(3):356-62. PubMed ID: 151764
[TBL] [Abstract][Full Text] [Related]
10. IgM antibodies against phenolic glycolipid I from Mycobacterium leprae in leprosy sera: relationship to bacterial index and erythema nodosum leprosum.
Schwerer B; Meeker HC; Sersen G; Levis WR
Acta Leprol; 1984; 2(2-4):394-402. PubMed ID: 6398598
[TBL] [Abstract][Full Text] [Related]
11. Lsr2 of Mycobacterium leprae and its synthetic peptides elicit restitution of T cell responses in erythema nodosum leprosum and reversal reactions in patients with lepromatous leprosy.
Saini C; Prasad HK; Rani R; Murtaza A; Misra N; Shanker Narayan NP; Nath I
Clin Vaccine Immunol; 2013 May; 20(5):673-82. PubMed ID: 23446220
[TBL] [Abstract][Full Text] [Related]
12. Serologic recognition of low molecular weight mycobacterial protein fractions in lepromatous patients with type II reactions (ENL).
Rada EM; Zambrano EA; Aranzazu N; Convit J
Int J Lepr Other Mycobact Dis; 2005 Sep; 73(3):222-5. PubMed ID: 16830648
[No Abstract] [Full Text] [Related]
13. Immunological status of ENL (erythema nodosum leprosum) patients: its relationship to bacterial load and levels of circulating IL-2R.
Vieira LM; Sampaio EP; Nery JA; Duppre NC; Albuquerque EC; Scheinberg MA; Sarno EN
Rev Inst Med Trop Sao Paulo; 1996; 38(2):103-11. PubMed ID: 9071029
[TBL] [Abstract][Full Text] [Related]
14. Sera of leprosy patients with type 2 reactions recognize selective sequences in Mycobacterium leprae recombinant LSR protein.
Singh S; Narayanan NP; Jenner PJ; Ramu G; Colston MJ; Prasad HK; Nath I
Infect Immun; 1994 Jan; 62(1):86-90. PubMed ID: 7505263
[TBL] [Abstract][Full Text] [Related]
15. Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.
Tadesse A; Shannon EJ
Clin Diagn Lab Immunol; 2005 Jan; 12(1):130-4. PubMed ID: 15642997
[TBL] [Abstract][Full Text] [Related]
16. Studies of human leprosy lesions in situ using suction-induced blisters: cell changes with IgM antibody to PGL-1 and interleukin-2 receptor in clinical subgroups of erythema nodosum leprosum.
Bhoopat L; Scollard DM; Theetranont C; Chiewchanvit S; Nelson DL; Utaipat U
Asian Pac J Allergy Immunol; 1991 Dec; 9(2):107-19. PubMed ID: 1807258
[TBL] [Abstract][Full Text] [Related]
17. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions.
Chakrabarty AK; Kashyap A; Sehgal VN; Saha K
Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112
[TBL] [Abstract][Full Text] [Related]
18. The use of the name Mycobacterium w for the leprosy immunotherapeutic bacillus creates confusion with M. tuberculosis-W (Beijing strain): a suggestion.
Talwar GP; Ahmed N; Saini V
Infect Genet Evol; 2008 Jan; 8(1):100-1. PubMed ID: 17766188
[No Abstract] [Full Text] [Related]
19. Critical residues of the Mycobacterium leprae LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions.
Singh S; Jenner PJ; Narayan NP; Ramu G; Colston MJ; Prasad HK; Nath I
Infect Immun; 1994 Dec; 62(12):5702-5. PubMed ID: 7525491
[TBL] [Abstract][Full Text] [Related]
20. Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum.
Scollard DM; Bhoopat L; Kestens L; Vanham G; Douglas JT; Moad J
Clin Immunol Immunopathol; 1992 Jun; 63(3):230-6. PubMed ID: 1623643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
